Quantified CSF antibody reactivity against myelin in multiple sclerosis

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Xingwen Sun - , Max Planck Institute of Experimental Medicine, University of Göttingen (Joint first author)
  • Mostafa Bakhti - , Max Planck Institute of Experimental Medicine, University of Göttingen (Joint first author)
  • Dirk Fitzner - , Max Planck Institute of Experimental Medicine, University of Göttingen (Joint first author)
  • Mareike Schnaars - , Max Planck Institute of Experimental Medicine, University of Göttingen (Author)
  • Niels Kruse - , University of Göttingen (Author)
  • Ünal Coskun - , German Center for Diabetes Research - Paul Langerhans Insitute Dresden (Partner: HMGU), German Center for Diabetes Research (DZD e.V.), Max Planck Institute of Molecular Cell Biology and Genetics (Author)
  • Christiane Kremser - , University of Bonn (Author)
  • Klaus Willecke - , University of Bonn (Author)
  • Ludwig Kappos - , University Hospital Basel (Author)
  • Jens Kuhle - , University Hospital Basel (Author)
  • Mikael Simons - , Max Planck Institute of Experimental Medicine, University of Göttingen (Author)

Abstract

Background
Synthesis of clonal IgG is a consistent feature of patients with multiple sclerosis (MS). Whether oligoclonal bands (OCBs) represent unspecific disease bystanders or active components in MS pathology is an open question. The aim of this study was to develop a method to quantify and compare the reactivity of cerebrospinal fluid (CSF) antibodies from patients with and without MS.

Methods
We collected CSF from 262 patients from two different cohorts, which included 148 patients with MS and 114 with other neurological diseases (OND). We established a highly sensitive electrochemiluminescence (ECL)-based assay to measure CSF antibody reactivity against purified myelin particles and biotin anchored liposomes. The diagnostic value of the ECL score against myelin particles was assessed with receiver operating characteristic curves.

Results
CSF from patients with MS have higher reactivity toward purified myelin particles as compared to those with OND with OCBs. Using liposomes with defined lipid compositions and myelin particles from ceramide synthase 2 (CerS2) knockout mice, we find that some of the CSF antibody reactivity is directed against cerebrosides.

Conclusion
The ECL-based assay system expands the currently available toolbox for the detection of autoantibodies in MS and related diseases.

Details

Original languageEnglish
Pages (from-to)1116-1123
Number of pages8
JournalAnnals of Clinical and Translational Neurology
Volume2
Issue number12
Publication statusPublished - Nov 2015
Peer-reviewedYes

External IDs

ORCID /0000-0003-4375-3144/work/142255279

Keywords